Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealth Net pharmacy formulary Coverage & Prior Aut…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    DraftHealth NetPolicy N/A

    Pharmacy and specialty drug formulary — coverage criteria (partial list)

    Customize your policy alerts

    Sign up for all Health Net policy alerts

    Know when Health Net releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs coverage, prior authorization (PA), quantity limits (QL), and medical necessity designations for pharmacy and specialty drugs; applies to prescribers and pharmacists processing Health Net member benefits.

    Policy Summary
    PayerHealth Net
    PolicyPharmacy and specialty drug formulary — coverage criteria (partial list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and document clinical justification for any product annotated with 'PA' and ensure dispensing stays within listed quantity limits (QL).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15+pages/sections referenced
    Multipledrugs with PA in extract
    Somedrugs with QL noted
    NCapplicable state
    severalbrand restrictions

    Coverage criteria and product annotations

    PA + Quantity Limit Requirements

    Coverage requires meeting payer-specified prior authorization and quantity limits as noted for each product.

    PA and QL apply where indicated: If a product entry is annotated with 'PA' the provider must obtain prior authorization before benefit payment; if annotated with 'QL' dispensing is limited to the specified quantity per time period shown for that product.See product-specific QL values (e.g., ACTEMRA QL 3.6 mL per 28 days; BENLYSTA QL 8 mL per 28 days; ENBREL QL 8 mL per 28 days)

    Specific clinical documentation requirements for individual PA requests are not included in this excerpt; follow Health Net PA submission processes and cite product labeling when available.

    Product-specific coverage flags

    Coverage and utilization management depend on the utilization flags shown on each formulary line.

    Formulary entry: Each drug line lists formulation, strength, and utilization flags (examples: PA, PA-NS, ST, QL, LA). Coverage is contingent on meeting any indicated prior authorization (PA/PA-NS), complying with step therapy (ST) where shown, and adhering to quantity limits (QL).
    Policy Summary
    PayerHealth Net
    PolicyPharmacy and specialty drug formulary — coverage criteria (partial list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization and document clinical justification for any product annotated with 'PA' and ensure dispensing stays within listed quantity limits (QL).
    SourceLink
    On This Page
    Coverage criteria and product annotationsCoding, NDCs and formulary flagsPrior authorization, documentation, and denial riskDocument context and scopeTerminology and abbreviationsStep therapy and tier indicationsQuantity limits (examples and per-product values)Biosimilar preferences and brand restrictions
    Refer to per-product QL entries (e.g., armodafinil QL 30 EA per 30 days; ZURZUVAE QL 28 EA per 365 days)

    This extract provides product-level flags rather than full clinical eligibility criteria.

    Formulary Coverage Annotations

    Formulary lines include inline annotations that indicate coverage constraints and limits.

    Formulary entry requirements: Drug coverage is indicated per product line with annotations such as 'PA' (prior authorization required), 'PA-NS' (prior authorization - non‑standard), 'ST' (step therapy), 'LA' (limited access), and 'QL' (quantity limit). Providers must obtain any required PA and request quantities consistent with the listed QL unless an approved exception is obtained.Examples of QL annotations in this segment: tramadol 50 mg QL (240 EA per 30 days); fentanyl buccal lozenge QL (120 EA per 30 days); acetaminophen-codeine oral solution QL (2700 mL per 30 days); morphine oral solution QL (900 mL per 30 days)

    Where 'PA' appears next to a product, documentation supporting medical necessity should be submitted with the PA request.

    The table excerpt includes several vaccine and preventive product entries that are explicitly designated NM (Not Medically Necessary) for specified age groups or indications. Examples from the listing include ABRYSVO (marked NM for age 19 and older) and multiple routine vaccine presentations (e.g., ADACEL and other immunizations) that show a second-column flag of NM for particular uses or populations. SHINGRIX is listed with a specific QL but also contains an NM designation for certain lines, with an exception note that a third dose may be considered post-transplant (PA required) where clinical criteria apply.

    Some biologic product listings restrict coverage to particular NDCs. For example, the HUMIRA entries state that Only Humira NDCs starting 00074 are covered, and quantity limits are provided per presentation (e.g., QL values shown alongside the covered NDC restriction). Providers must confirm the NDC on the claim matches the covered NDCs indicated in the formulary.

    Within this partial extract there is no standalone exclusions section; the document fragment does not present an explicit list of items labeled as excluded. Formulary rows instead use inline flags (e.g., PA, QL, PA-NS, NM) to convey coverage constraints.

    The excerpt functions as a product index/formulary listing and does not include a separate exclusion list. Many products are enumerated with utilization-designation flags and quantity limits, but no explicit global exclusion statements or a consolidated exclusion table appear in these chunks.

    Numerous individual table entries are explicitly marked NM (Not Medically Necessary) for specified ages or uses. Examples include immunization entries (multiple vaccines show a second-column value of NM), and SHINGRIX lines that identify NM in some rows while noting limited exceptions (e.g., post‑transplant dosing requiring PA). These line-level NM flags indicate the product is not covered for that listed indication or population unless otherwise specified.

    Certain portions of the extracted listing do not contain explicit Not Medically Necessary language; many rows instead show utilization controls such as PA, PA-NS, and QL. In this fragment (e.g., behavioral health/CNS agents) product lines are shown with PA/QL markers but not with explicit NM text.

    This excerpt does not systematically list any items as broadly not medically necessary. Coverage constraints here are primarily indicated by line annotations such as PA, QL, and occasional PA-NS flags rather than a declarative NM exclusion for the listed products.

    Coding, NDCs and formulary flags

    Header codes/snippetsmixed
    LXUnknown short code appearing in header: 'LX rizatriptan Smg 53'
    Listed drug products and strengthsmixed
    bosentan oral tablet 125 mg, 62.5 mgbosentan oral tablet formulations listed with PA/LA/QL notations
    BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE,50-25 MCG/DOSEinhaler product with QL (60 EA per 30 days) indicated
    FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/MLbiologic with PA; LA; QL (1 ML per 28 days)
    HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIThereditary angioedema product with PA; LA; QL (30 EA per 30 days)
    KALYDECO ORAL GRANULES IN PACKET 13.4 MG,5.8 MGcystic fibrosis modulator with PA; QL (56 EA per 28 days)
    OFEV ORAL CAPSULE 100 MG, 150 MGantifibrotic with PA; QL (60 EA per 30 days)
    TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75cystic fibrosis modulator with PA; QL (84 EA per 28 days)
    XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/MLomalizumab product with PA; QL (8 ML per 28 days)
    PROMACTA ORAL POWDER IN PACKET 12.5 MGeltrombopag with PA; LA; QL (360 EA per 30 days)
    XARELTO ORAL TABLET 10 MG,20 MGrivaroxaban with QL (30 EA per 30 days)
    NDC/Formulation listings and plan annotations (no formal CPT/HCPCS/ICD codes in this segment)mixed
    No codes listed
    Drug list (product-level entries)NDC-like/product
    No codes listed
    Formulary flags and quantity codesmixed
    PA-NSPrior authorization - non-standard (as listed)
    PAPrior authorization required
    QL (28 EA per 28 days)Quantity limit example
    LALimited access (plan designation)
    BDBenefit/designation code as listed
    B/DBenefit/department designation
    NTNoted as NT in list
    Selected dermatologic formulations with QL/PA annotationsNDC/description
    metronidazole topical gel 0.75%listed with QL (45 GM per 30 days)
    metronidazole topical lotion 0.75%listed with QL (59 ML per 30 days)
    myorisan oral capsule 10 mg,20 mg,30 mg,40 mglisted
    tazarotene topical cream 0.1%PA; QL (60 GM per 30 days)
    tazarotene topical gel 0.05%,0.1%PA
    tretinoin topical cream 0.025%,0.05%,0.1%PA; QL (45 GM per 30 days)
    tretinoin topical gel 0.01%,0.025%PA; QL (45 GM per 30 days)
    tretinoin topical gel 0.05%PA; QL (45 GM per 30 days)
    Ophthalmic agents with PA/QL annotationsNDC/description
    betaxolol ophthalmic 0.5%listed
    timolol maleate ophthalmic 0.25%,0.5%listed
    TOBRADEX ophthalmic ointment 0.3-0.1%listed
    CYSTARAN ophthalmic drops 0.44%PA; LA (limited access) indicated
    OXERVATE ophthalmic drops 0.002%PA indicated
    XDEMVY ophthalmic drops 0.25%PA; QL (10 ML per 42 days)
    Specialty biologics and injectablesNDC/description
    ACTEMRA ACTPEN 162 mg/0.9 mLPA; QL (3.6 ML per 28 days)
    BENLYSTA IV 120 mg,400 mgPA
    BENLYSTA SC 200 mg/mLPA; LA; QL (8 ML per 28 days)
    ENBREL products (various)PA; QL (8 ML per 28 days)
    HUMIRA products (various)PA; Only Humira NDCs starting 00074 are covered; QL (varies)
    Bone metabolism and other selected agents with QL/PANDC/description
    colchicine 0.6 mgQL (120 EA per 30 days)
    alendronate oral solution 70 mg/75 mLQL (300 ML per 28 days)
    PROLIA subcutaneous syringe 60 mg/mLQL (1 ML per 180 days)
    TERIPARATIDE pen injector 20 mcg/dosePA; QL (2.48 ML per 28 days); Only specific NDC covered for one product
    NDC-specific coverageNDCCovered
    NDC 47781065289Only Teriparatide NDC covered (document states only this NDC is covered)
    Drug listing (no explicit billing codes in extract)mixed
    N/AThis extract lists NDC/CPT codes are not provided; items are drug name and formulation entries with utilization flags.
    Quantity Limits (examples)mixed
    QL (240 EA per 30 days)Quantity limit for tramadol 50 mg tablets
    QL (2700 ML per 30 days)Quantity limit for acetaminophen-codeine oral solution
    QL (360 EA per 30 days)Quantity limit for acetaminophen-codeine oral tablet 300-15 mg
    Quantity Limits (additional examples)mixed
    QL (120 EA per 30 days)Quantity limit shown for fentanyl buccal lozenge on a handle
    QL (10 EA per 30 days)Quantity limit for fentanyl transdermal patch 72 hour 100 mcg/hr
    QL (180 EA per 30 days)Quantity limit for endocet 10-325 mg
    Product-index mappings (textual)mixed
    No codes listed
    Topical quantity limits — examples
    Metronidazole topical gel 0.75%QL 45 GM per 30 days
    Metronidazole topical lotion 0.75%QL 59 ML per 30 days
    Tazarotene topical cream 0.1%QL 60 GM per 30 days; PA
    Tretinoin topical formulationsQL 45 GM per 30 days (cream/gel as listed); PA on select strengths
    Biologic quantity-limit examples
    ACTEMRA ACTPEN 162 mg/0.9 mLQL 3.6 mL per 28 days; PA
    BENLYSTA subcutaneous 200 mg/mLQL 8 mL per 28 days; PA; LA
    ENBREL (various presentations)QL 8 mL per 28 days; PA
    Quantity-limit examples (varied)
    PROLIA subcutaneous syringe 60 mg/mLQL 1 mL per 180 days
    DESCOVY oral tabletQL 30 EA per 30 days
    SKYRIZI subcutaneous wearable injectorQL 1.2 mL per 56 days (specific wearable presentation) or QL 6 mL per 365 days for other presentations
    BONSITY / Teriparatide penQL (Teriparatide) 2.48 mL per 28 days; Only specific NDC covered for one pen formulation
    INVEGA TRINZA per 90 days — strength-specific volumes
    INVEGA TRINZA 273 mg / 0.88 mLQL 0.88 mL per 90 days
    INVEGA TRINZA 410 mg / 1.32 mLQL 1.32 mL per 90 days
    INVEGA TRINZA 546 mg / 1.75 mLQL 1.75 mL per 90 days
    INVEGA TRINZA 819 mg / 2.63 mLQL 2.63 mL per 90 days
    ZURZUVAE annual limits by strength
    ZURZUVAE 20 mg / 25 mgQL 28 EA per 365 days
    ZURZUVAE 30 mgQL 14 EA per 365 days

    Prior authorization, documentation, and denial risk

    Prior Authorization

    Prior authorization required when indicated

    Many drugs listed in the formulary table are subject to prior authorization (PA) and/or limited-access (LA) controls. When a drug entry includes PA, PA-NS, LA, or PA; LA flags, providers must obtain prior authorization before the plan will cover the medication. Claims submitted without required prior authorization are at risk for denial.

    • Apply PA when table shows 'PA', 'PA-NS', or 'PA; LA'.
    • Limited-access (LA) items require use of specified distribution channels or additional plan documentation.
    Documentation Required

    Topical agents PA/QL

    Topical dermatologic agents in the formulary may carry PA and/or quantity limits (QL). Examples include branded topical patches and compounded topical products that show 'PA' or explicit QL entries; providers should include indication and quantity justification when requesting coverage.

    • Adhere to QL entries (e.g., topical patches QL (90 EA per 30 days)).
    • Submit clinical rationale for non-routine topical products marked PA.
    Prior Authorization

    INBRIJA PA & QL

    INBRIJA inhalation capsules are listed with PA and a specific quantity limit: PA; QL (300 EA per 30 days). Prior authorization requests for INBRIJA must include the clinical indication and the quantity requested consistent with this QL.

    • INBRIJA (42 mg) — PA; QL (300 EA per 30 days).
    • Include diagnosis and dosing schedule when submitting PA.
    Note

    Prior authorization requirement implied from table

    The table format itself implies prior authorization and utilization controls where flags (PA, PA-NS, LA, QL, BD, B/D, ST) appear. Providers should treat flagged products as requiring prior authorization or subject to plan limits even when a full clinical rule set is not reproduced here.

    • Treat any product with PA/PA-NS/LA/BD/ST as requiring prior approval.
    • When no explicit clinical criteria are listed in this excerpt, use the formulary flags as the operational trigger for PA submission.
    Prior Authorization

    Prior authorization required for selected specialty inhalation agents

    Selected specialty inhalation and nebulized agents (e.g., ARIKAYCE, CAYSTON, inhaled tobramycin entries, various nebulized budesonide/formoterol products) are annotated PA and often LA/QL. These high-cost inhalation therapies require prior authorization and may be limited to specific quantities or distribution channels.

    • ARIKAYCE inhalation suspension — PA; LA.
    • CAYSTON inhalation solution — PA; LA; QL (84 ML per 56 days).
    • Nebulized agents with PA or LA must have supporting clinical documentation.
    Denial Risk

    Quantity-limit related denial risk

    Claims exceeding listed quantity limits (QL) or that do not include required PA/LA documentation are at risk for denial. Quantity-limit exceedances should be anticipated and addressed in the initial PA submission with dose frequency and duration details.

    • Claims exceeding QL (e.g., INBRIJA 300 EA/30 days, various oncology QLs) may be denied if not authorized.
    • Request exceptions only with supporting medical necessity documentation.
    Denial Risk

    Utilization control triggers denial

    Utilization controls noted in the table (PA, PA-NS, LA, QL, BD, B/D, ST) are active denial triggers. Prescriptions lacking the required authorization or exceeding QL may be rejected at point-of-sale or on medical claim adjudication.

    • PA-NS and PA entries commonly apply to oncology and specialty oral agents; absence of PA may lead to denial.
    • BD/B/D entries indicate specialty or limited distribution — confirm dispensing channel prior to submission.
    Prior Authorization

    PA/QL present for biologics and topicals

    Many high-cost biologics and specialty injectables are marked PA and include QL constraints (e.g., DUPIXENT, COSENTYX, SKYRIZI, STELARA, TREMFYA, ACTEMRA, BENLYSTA, ENBREL, HUMIRA). Prior authorization submissions should include prior treatment history, diagnosis, and intended dosing consistent with plan QLs.

    • Biologics commonly require PA and have per-period ML or EA limits (see QL entries adjacent to each product).
    • Provide prior therapy and objective measures when applicable (e.g., trial of preferred agents if applicable).
    Prior Authorization

    PA for selected ophthalmic agents

    Certain specialty products listed for ophthalmic use (e.g., CYSTARAN, OXERVATE) and select other specialty therapies are marked PA and/or LA. For ophthalmic agents flagged PA/LA, include ocular diagnosis, previous therapies, and anticipated duration of therapy in the PA documentation.

    • CYSTARAN ophthalmic drops — PA; LA.
    • OXERVATE ophthalmic drops — PA.
    Documentation Required

    Required documentation for PA/LA/QL

    When PA is indicated (PA, PA-NS, PA; LA), submit documentation supporting medical necessity: diagnosis, relevant prior treatments, dosing regimen, and the quantity requested. For LA or BD items, confirm the permitted dispensing site or specialty pharmacy before submitting an authorization request.

    • Include prior treatment attempts and outcomes when applicable.
    • For LA/BD items, document the requested dispensing channel or confirm specialty pharmacy availability.
    Documentation Required

    Documentation for PA/QL requests

    Documentation expectations include: clinical indication consistent with FDA labeling or accepted off‑label use, dosing and duration, prior therapy history, and justification for quantities exceeding routine dosing when requesting exceptions. Evidence of medical necessity will be required for PA approval.

    • Evidence of medical necessity: diagnosis, labs or objective measures (if applicable), prior agent failures or intolerances.
    • When requesting a quantity-limit override, include expected duration and monitoring plan.
    Step Therapy

    Tier/step and preferred/step implications

    Some formulary entries include tiering, step-therapy indicators (ST), or numeric tier labels (e.g., 1 =, 2 =, 3 =, 4 =, 5^ =). While step therapy rules are not fully reproduced in this excerpt, providers should recognize that step edits or preferred-product requirements may apply and consult the complete policy or PBM portal for specific step requirements.

    • Numeric tier indicators reflect formulary tiering or specialty tiers.
    • ST marking denotes step-therapy may apply — check complete policy for required prior agents.
    Note

    No explicit authorization or denial criteria present in excerpt

    Some segments of the table excerpt do not include explicit clinical criteria or authorization instructions. Where no authorization requirements are specified in this fragment, follow the plan's standard PA submission process and reference the formulary flags; contact the plan's provider helpdesk for missing or ambiguous guidance.

    • If the table segment lacks PA/QL text, verify coverage via provider portal or contact Health Net.
    • Do not assume coverage in absence of explicit 'NM' or 'covered' status — use plan systems to confirm.

    Document context and scope

    Background: the provided material is a partial formulary/index from Health Net's pharmacy and specialty drug policy. It enumerates products, formulations, and plan annotations (e.g., PA, QL, NM, LA) at the line level to indicate coverage requirements and utilization management controls rather than providing full clinical criteria within this extract.

    Terminology and abbreviations

    Definitions — PA / QL / NM / LA
    PAPrior authorization required before benefit payment when 'PA' appears in table
    QLQuantity limit — maximum units allowed per specified time period as listed (e.g., '14 EA per 28 days', '4 ML per 28 days')
    NMNot Medically Necessary — designation appearing in the table for certain uses or ages
    LALimited Approval / limited access designation shown as 'LA' adjacent to product entries
    Coverage shorthand — PA / PA-NS / ST
    PA (shorthand)'PA' used in listings to indicate prior authorization is required
    PA-NS'PA-NS' marker used for prior authorization - non-standard entries
    ST'ST' indicates Step Therapy is present for some agents (rules not included in excerpt)
    Quantity limit (QL) shorthand and examples
    QL examples (format)Quantity limits shown as e.g., '30 EA per 30 days', '120 EA per 30 days', '3 ML per 28 days'
    QL with PASome entries show both 'PA' and explicit QL (e.g., fentanyl buccal lozenge PA; QL 120 EA per 30 days)
    QL timeframesQLs use days, 28-day, 30-day, 90-day or annual (365 days) periods as specified per product
    Other table annotations — LA / BD / NM
    LA (Limited Approval)'LA' appears next to some products indicating limited access or restricted benefit/site; check plan rules
    B/D or BDBenefit/designation markers (e.g., 'B/D', 'BD Preferred') used to indicate coverage preferences
    NM labeling'NM' appears for certain vaccines or age-limited indications (e.g., SHINGRIX entries)
    QL shorthand examples
    QL sample formatExamples in table: '30 EA per 30 days', '14 EA per 7 days', '300 ML per 28 days'
    QL unitsUnits appear as EA (each), ML (milliliter), GM (gram) depending on formulation
    Time windowsLimits specified per 7, 28, 30, 56, 90, 180, or 365 day periods
    LA / limited access examples
    FASENRA PEN 30 mg/mLQL 1 mL per 28 days; PA; LA
    FASENRA syringe 10 mg/0.5 mLQL 0.5 mL per 28 days
    Bosentan oral tabletsQL 10.7 GM per 30 days; QL 60 EA per 30 days noted in listing
    PA-NS (Prior Authorization - Non-Standard)
    PA-NSMarker 'PA-NS' indicates prior authorization - non-standard; appears in multiple oncology and specialty listings
    Use in listingsPA-NS entries often accompany QL and LA flags (document shows many PA-NS examples)
    Quantity limit (QL) — definition and examples
    QL (format) reiteratedQuantity limit defined as maximum units allowed per specified time period (e.g., '30 EA per 30 days')
    Examples in table'30 EA per 30 days', '120 EA per 30 days', '84 ML per 56 days' as shown for various products
    ST — Step Therapy (marker explanation)
    ST (Step Therapy)'ST' indicates step therapy is applied for specified products (examples: AUVELITY flagged ST); explicit sequences not included here
    PresenceStep therapy markers appear in product lines though full step rules are not present in excerpt

    Step therapy and tier indications

    Summary
    No explicit step-therapy sequences are listed in the provided formulary extract; entries show utilization flags such as PA, QL, LA, PA-NS, and NM but do not define step-by-step required prior agents or tiers.
    Product / Note
    Some insulin and device listings show 'BD Preferred' or brand restrictions (e.g., Novolin/Relion entries note 'brand RELION not covered'), implying preferred-brand or formulary-preference behavior that may reflect step or therapeutic interchange intent.
    Annotated Tier Indicators
    Several antiretroviral and specialty agents are annotated with numeric/tier markers (examples: multiple HIV agents marked '5^' or '4'), and high-tier oncology agents also show '5^' — these tier markers imply specialty or higher-tier coverage status though explicit step rules are not provided.
    Formulary NotationMeaning (per extract)
    1 =, 2 =, 3 =, 4 =, 5^ =
    Numeric indicators used next to product entries to denote formulary tier/coverage category; '5^' frequently marks specialty/high-tier products. The extract shows these markers but does not specify step-therapy sequences.
    ProductAccess Restriction
    HUMIRA (various pen/syringe presentations)
    Coverage restricted to specific NDCs — entries state 'Only Humira NDCs starting 00074 are covered', which functions as an access restriction before other brands are eligible.
    Formulary AnnotationImplication
    Numeric tier markers (e.g., '1 =', '2 =', '5^') and flags (PA; QL; LA)
    These annotations indicate tier assignments and utilization controls (prior authorization, quantity limits, limited access) that determine coverage category and access requirements for each listed drug line.
    ProductST (Step Therapy) Designation
    FANAPT titration pack
    Marked 'ST' in the extract (e.g., FANAPT titration pack shows 'ST; QL ...'), indicating a step therapy edit applies before coverage.
    OPIPZA oral film (various strengths)
    Entries show 'PA; QL ... = ST' indicating step therapy requirement applies to these products prior to coverage.
    AUVELITY
    Listed with 'ST' designation in the extract indicating step therapy applies (specific step details not provided in excerpt).
    ObservationSource Example
    Numeric tier indicators (1,2,3,4,5^) appear throughout the formulary and likely reflect tier or step status; explicit step sequences are not specified in the provided extract.
    Examples include antiretrovirals and specialty agents annotated '5^' and other products with '1 =' through '4 =' markers (see multiple entries in the extract).
    Summary
    The provided extract does not contain explicit step-therapy sequences or required predecessor agents; where step edits are implied the table uses 'ST' or tier markers but does not list step-by-step rules in this segment.

    Quantity limits (examples and per-product values)

    BETASERON quantity limit
    BETASERONQL 14 EA per 28 days
    ContextListed as QL adjacent to product in injectable/biologic section
    PEGASYS — presentation-dependent limits
    PEGASYS subcutaneous solution 180 mcg/mLQL 4 mL per 28 days; PEGASYS syringe 180 mcg/0.5 mL QL 2 mL per 28 days
    Multiple presentationsDifferent PEGASYS presentations have different QLs per listing
    CINACALCET quantity limit
    CINACALCET oral tablet (30/60/90 mg)QL 60 EA per 30 days (listed for 30 mg and 60 mg strengths)
    StrengthsListing shows 30 mg and 60 mg strengths with same 60 EA per 30 days QL
    SHINGRIX quantity limit
    SHINGRIX (intramuscular)QL 2 EA per 999 days; NM noted for some age groups and PA required for certain post-transplant dosing
    NotesListing indicates possible third-dose consideration post-transplant with PA
    Various quantity-limit examples
    Examples across product typesVarious entries show QLs such as '60 EA per 30 days', '3.6 mL per 28 days', '180 mL per 30 days' depending on product
    Forms and unitsQLs appear for EA, ML, GM depending on formulation (injectable, inhalation, topical)
    Bosentan — QL and annotations
    bosentan oral tablet 125 mg / 62.5 mgQL 10.7 GM per 30 days; listing also shows QL 60 EA per 30 days and PA/LA annotations
    Coverage flagsEntry annotated with PA; LA; QL in table
    FASENRA — pen/syringe QL examples
    FASENRA pen 30 mg/mLQL 1 mL per 28 days; PA; LA
    FASENRA syringe 10 mg/0.5 mLQL 0.5 mL per 28 days (syringe presentation)
    KALYDECO quantity-limit example
    KALYDECO oral tablet 150 mgQL 56 EA per 28 days; PA and LA annotations present for some presentations
    Granules and packet formsGranules/packets also listed with same 56 EA per 28 days QL
    Nebivolol / Atorvastatin — QL per strength
    Nebivolol (various strengths)QL 30 EA per 30 days or QL 60 EA per 30 days depending on strength
    AtorvastatinQL 30 EA per 30 days for some entries
    Atorvastatin quantity-limit example
    Atorvastatin oral tablet (various strengths)QL 30 EA per 30 days (listed for some tiered entries)
    ContextShown in cholesterol/lipid section with QL annotation
    Vancomycin — various QL limits
    Vancomycin IV/oral preparationsMultiple QLs depending on formulation: e.g., 4000 mL per 10 days (IV piggyback), 20 EA per 10 days (oral capsule) — see listing
    Formulation-specific limitsDifferent QLs apply to recon solutions, piggybacks and oral capsules
    Inhaled antibiotics — QL examples (CAYSTON / ARIKAYCE / tobramycin)
    CAYSTON inhalation solutionQL 84 mL per 56 days; PA; LA
    ARIKAYCE inhalation suspensionPA; LA noted in listing
    Tobramycin inhalationExample QLs include 280 mL per 28 days depending on presentation
    DESCOVY — QL example
    DESCOVY oral tabletQL 30 EA per 30 days
    ContextListed in antiretroviral section with 30 EA per 30 days QL
    PAXLOVID — QL example
    PAXLOVID dose packQL 20 EA per 90 days (150/100 mg pack) or QL 30 EA per 90 days for alternate packings
    Pack-dependent limitsDifferent PAXLOVID pack sizes have distinct QLs per 90-day window
    PREZISTA — suspension QL example
    PREZISTA oral suspension 100 mg/mLQL 400 mL per 30 days
    PREZISTA tabletsSeparate QLs for tablet strengths (e.g., 240 EA per 30 days for 150 mg)
    Voriconazole — QL example
    Voriconazole oral tablet 200 mgQL 120 EA per 30 days
    Other voriconazole formulationsSuspension and IV presentations have PA and different QLs noted
    ALECENSA — QL example
    ALECENSA oral capsule 150 mgQL 240 EA per 30 days; PA-NS; LA
    ContextListed in oncology section with PA-NS and QL
    Dasatinib / sunitinib — QL examples
    Dasatinib (selected strengths)QL 30-60 (EA) per month depending on strength
    Sunitinib malate oral capsuleQL 28 EA per 28 days
    KISQALI — QL examples
    KISQALI various packingsQL ranges shown 21-91 EA per 28-30 days depending on packing/ dosing regimen
    ContextPack-specific QLs listed in oncology regimen entries
    IMBRUVICA — QL example
    IMBRUVICA (various formulations)QL 30 EA per 30 days noted for some listings
    Formulation variationDifferent presentations may have same standard monthly QL
    PIQRAY — QL examples
    PIQRAY oral tabletQL 28 EA per 28 days (200 mg/day) and QL 56 EA per 28 days for alternate dosing regimens
    PA-NSListed with PA-NS in oncology section
    Sunitinib — QL example
    Sunitinib malate oral capsuleQL 28 EA per 28 days
    ContextOncology oral targeted agent with PA-NS and QL in listing
    VENCLEXTA — QL example
    VENCLEXTA oral tablet 10 mgQL 14 EA per 7 days (as listed)
    Pack/starting regimensSpecific starting packs / dose packs also annotated with QL elsewhere in oncology section
    ZEJULA — QL range example
    ZEJULA oral tabletQL range 30-90 EA per 30 days depending on strength/presentations
    NotesDifferent tablet strengths/prescribed regimens determine the specific QL
    DUPIXENT — pen and syringe volumes
    DUPIXENT PEN 200 mg / 1.14 mLQL 4.56 mL per 28 days
    DUPIXENT PEN 300 mg / 2 mLQL 8 mL per 28 days
    DUPIXENT syringe presentationsSyringe 200 mg/1.14 mL QL 4.56 mL per 28 days; syringe 100 mg QL 1.34 mL per 28 days
    Fluorouracil topical — QL example
    Fluorouracil topical cream 5%QL 40 GM per 30 days
    Fluorouracil topical solutionQL 10 ML per 30 days (solution presentations)
    Imiquimod — QL example
    Imiquimod topical cream 5% (packet)QL 24 EA per 28 days
    Presentation noteListed as packet with QL in dermatologic section
    Lidocaine topical patch — QL example
    Lidocaine topical adhesive patch, medicated 5%QL 90 EA per 30 days; PA noted in listing
    Lidocaine other formsTopical ointment/solutions have separate QLs (e.g., 50 GM per 30 days)
    Clobetasol topical — QL example
    Clobetasol topical gel 0.05%QL 60 GM per 28 days
    Scalp solutionClobetasol scalp solution QL 30 GM per 28 days (other conversions shown)
    COSENTYX — QL examples
    COSENTYX (various presentations)QL 10 mL per 28 days (pen presentations noted)
    COSENTYX 75 mg/0.5 mLQL 2.5 mL per 28 days
    COSENTYX 75 mg/0.5 mL — volume example
    COSENTYX 75 mg/0.5 mL (specific)QL 2.5 mL per 28 days
    Other COSENTYX formsFull biologic section lists 10 mL per 28 days for some presentations
    SKYRIZI — QL examples
    SKYRIZI subcutaneous pen 150 mg/mLQL 6 mL per 365 days (subcutaneous); SKYRIZI IV solution QL 30 mL per 180 days
    Notes on wearable injectorWearable injector presentations have separate per-56-day QLs (see SKYRIZI wearable entries)
    STELARA — QL examples
    STELARA 45 mg/0.5 mLQL 0.5 mL per 28 days; PA indicated for listed presentations
    STELARA 90 mg/mLQL 1 mL per 28 days (syringe 90 mg/mL) depending on listing
    TREMFYA — induction and maintenance QLs
    TREMFYA pen induction (200 mg/2 mL)QL 12 mL per 180 days (induction PK-CROHN presentation)
    TREMFYA maintenance presentationsQL 2 mL per 28 days
    TREMFYA (maintenance) — QL example
    TREMFYA maintenanceQL 2 mL per 28 days
    Induction noteInduction PK-CROHN pen shows larger 12 mL per 180 days QL
    Metronidazole / tazarotene / tretinoin topical QLs
    Metronidazole topical gel 0.75%QL 45 GM per 30 days
    Tazarotene topical cream 0.1%QL 60 GM per 30 days; PA on cream presentation
    Tretinoin topical cream/gelQL 45 GM per 30 days; PA indicated on multiple formulations
    Ophthalmic agents — PA/LA examples
    CYSTARAN ophthalmic drops 0.44%PA; LA (limited access) indicated in listing; QL not specified in cited chunk
    OXERVATE ophthalmic drops 0.002%PA indicated in listing
    ACTEMRA — pen/syringe QL
    ACTEMRA ACTPEN 162 mg/0.9 mLQL 3.6 mL per 28 days; PA indicated
    ACTEMRA syringe presentationsSyringe listed with same 3.6 mL per 28 days QL
    Colchicine — QL example
    Colchicine 0.6 mgQL 120 EA per 30 days
    Presentation noteListed for capsule and tablet forms with same QL
    PROLIA / Inflectra — QL examples
    PROLIA (denosumab) 60 mg/mL syringeQL 1 mL per 180 days
    Inflectra IV recon soln 100 mgQL 20 EA per 30 days
    PROLIA / Teriparatide — QL and NDC note
    Prolia / STOBOCLO subcutaneous syringe 60 mg/mLQL 1 mL per 180 days
    Teriparatide subcutaneous pen injectorQL 2.48 mL per 28 days; Only Teriparatide NDC 47781065289 is covered for one listed presentation
    Teriparatide — QL and NDC-specific coverage
    Teriparatide pen injectorQL 2.48 mL per 28 days; PA noted on some pen entries
    NDC-specific coverageOnly Teriparatide NDC 47781065289 is covered for specified listing
    Alosetron — QL example
    Alosetron 0.5 mg / 1 mgQL 60 EA per 30 days; PA applies
    Formulation noteBoth 0.5 mg and 1 mg strengths listed with same QL
    Inflectra — QL example
    Inflectra IV recon soln 100 mgQL 20 EA per 30 days; PA indicated
    ContextListed in biologic/infusion section
    SKYRIZI IV and wearable — QL examples
    SKYRIZI IV solution 60 mg/mLQL 30 mL per 180 days; PA indicated
    SKYRIZI wearable injectorSeparate per-56-day QLs (1.2 mL or 2.4 mL) depending on wearable presentation
    Armodafinil — QL examples
    Armodafinil (150-250 mg)QL 30 EA per 30 days; PA indicated for some strengths/presentations
    Lower-strength armodafinil50 mg listed with QL 60 EA per 30 days
    INVEGA TRINZA — per-90-day volume range
    INVEGA TRINZA (various strengths)QL 0.88 - 2.63 mL per 90 days depending on strength (0.88, 1.32, 1.75, 2.63 mL listed)
    INVEGA SUSTENNA/HAFYERASeparate per-28/180-day QLs also listed for other INVEGA products
    ZURZUVAE — annual limits
    ZURZUVAE 20 / 25 mgQL 28 EA per 365 days
    ZURZUVAE 30 mgQL 14 EA per 365 days
    Note

    Biosimilar preferences and brand restrictions

    Note